SCHEMBL4674982

SCHEMBL4674982

O=C(Cc1cc(Cc2ccccn2)cs1)C(=O)c1nn[nH]n1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR2 O15552 1/20 0.35
POLB P06746 2/20 0.34
CES1 P23141 1/20 0.34
NCEH1 Q6PIU2 1/20 0.34
ALDH1A1 P00352 2/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
CXCR3 P49682 3/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
PDE5A O76074 1/20 0.32
PDE1A P54750 1/20 0.32
PDE1B Q01064 1/20 0.32
PDE1C Q14123 1/20 0.32
KMT2A Q03164 1/20 0.32
IDO1 P14902 1/20 0.32
RAB9A P51151 1/20 0.32
HPGD P15428 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP2D6 P10635 1/20 0.31
MAPT P10636 1/20 0.31
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4675534 0.92 FFAR2 (0.35) FFAR2POLBCES1NCEH1ALDH1A1
SCHEMBL4676619 0.86 CES1 (0.42) FFAR2CES1NCEH1ALDH1A1
SCHEMBL4675134 0.84 POLB (0.34) POLBALDH1A1SMN1; SMN2L3MBTL1KMT2A
SCHEMBL4676131 0.83 SMN1; SMN2 (0.35) FFAR2POLBCES1NCEH1ALDH1A1
SCHEMBL4671551 0.83 CES1 (0.32) FFAR2POLBCES1NCEH1TSHR
SCHEMBL4675276 0.81 FFAR2 (0.35) FFAR2POLBCES1NCEH1ALDH1A1
SCHEMBL4673451 0.81 PTPN1 (0.35) CES1NCEH1SMN1; SMN2CXCR3KMT2A
SCHEMBL4675849 0.80 FFAR2 (0.35) FFAR2POLBCES1NCEH1CXCR3
SCHEMBL4671506 0.80 PDE5A (0.36) FFAR2POLBCES1NCEH1ALDH1A1
SCHEMBL4676508 0.80 PDE5A (0.34) FFAR2POLBCES1NCEH1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 FFAR2 2618/4885POLB 58/4885CES1 445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.